Discovery of novel cycloalkyl-fused thiazole-based pyrimidine derivatives as highly potent CDK2 inhibitors with promising antitumor activity
Bioorganic Chemistry · 2026
DOI: 10.1016/j.bioorg.2025.109385 ↗Kurz gefasst
Fachartikel in der Zeitschrift Bioorganic Chemistry, 2026. Verfasst von Wen-Ming Tan und 8 weiteren Autor:innen. Beteiligte Einrichtung: Jiangmen Central Hospital, Jiangmen 529030, China. Hauptthemen laut MEDLINE: Cyclin-Dependent Kinase 2, Antineoplastic Agents, Pyrimidines, Thiazoles. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 33 Literaturangaben. Gefördert von: Zhejiang Traditional Chinese Medicine Administration, Jiangmen Science and Technology Bureau, Basic and Applied Basic Research Foundation of Guangdong Province.
Abstract (Originalsprache)
CDK2 has a pivotal role in the cell cycle process, and regulates a broad range of important biological processes, and recent investigations have revealed that inhibiting CDK2 can reverse cancer resistance to CDK4/6 inhibitors, indicating the therapeutic promise of CDK2 as an attractive therapeutic target in cancer treatment. Herein, we discovered a novel class of cycloalkyl-fused thiazole-substituted 2,4-diaminopyrimidine derivatives as potent CDK2 inhibitors. Especially, compound 12c significantly inhibited CDK2 (IC50 = 4.7 nM) which was 7-fold greater than positive control AZD5438, and exhibited remarkable antiproliferative efficacy toward HCT-116, A549, HeLa, and MCF-7 cells with the IC50s of 1.29-6.14 μM. Mechanism research revealed that 12c dose-dependently caused G2/M cell cycle arrest, and promoted apoptosis of HCT116. Overall, these findings present valuable leads and are of great importance to develop highly potent CDK2 inhibitors for cancer therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Jiangmen Central Hospital, Jiangmen 529030, China.
- Department of Pharmacy, Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China.
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, China.
- Jiangmen Central Hospital, Jiangmen 529030, China.. Electronic address: zhangbei@jmszxyy.com.cn.
- Guangdong Provincial Key Laboratory of New Drug Screening, School of Pharmaceutical Science, Southern Medical University, Guangzhou 510515, China.. Electronic address: plzhao@smu.edu.cn.
Förderung
- Zhejiang Traditional Chinese Medicine Administration
- Jiangmen Science and Technology Bureau
- Basic and Applied Basic Research Foundation of Guangdong Province
Zitieren
APA
Tan, W. M., Fu, Y., Chen, J. W., Diao, P. C., Lin, Y. K., Zou, Z. K., Jian, X. E., Zhang, B., & Zhao, P. L. (2026). Discovery of novel cycloalkyl-fused thiazole-based pyrimidine derivatives as highly potent CDK2 inhibitors with promising antitumor activity. Bioorganic Chemistry. https://doi.org/10.1016/j.bioorg.2025.109385
Vancouver
Tan WM, Fu Y, Chen JW, Diao PC, Lin YK, Zou ZK, et al. Discovery of novel cycloalkyl-fused thiazole-based pyrimidine derivatives as highly potent CDK2 inhibitors with promising antitumor activity. Bioorganic Chemistry. 2026. doi:10.1016/j.bioorg.2025.109385
BibTeX
@article{Tan2026,
author = {Tan, Wen-Ming and Fu, Yu and Chen, Jun-Wei and Diao, Peng-Cheng and Lin, Yu-Kang and Zou, Zhong-Kai and Jian, Xie-Er and Zhang, Bei and Zhao, Pei-Liang},
title = {Discovery of novel cycloalkyl-fused thiazole-based pyrimidine derivatives as highly potent CDK2 inhibitors with promising antitumor activity},
journal = {Bioorganic Chemistry},
year = {2026},
doi = {10.1016/j.bioorg.2025.109385}
}
EUVIMED